Almost 90,000 people in Andalusia have already received both doses.
Andalusia has administered a total of 300,031 vaccines against Covid-19 since the start of the vaccination campaign on 27 December 2020 and until 31 January 2021, representing 90.64% of the doses received. The doses were distributed to people belonging to the defined risk groups: elderly people in care homes, social and health care workers and Corona frontline health workers.
Due to the phased arrival of the vaccines from Pfizer/Biontech and Moderna and in relation to supply cuts, the first batch of doses for the risk group was completed in the last week of January, and administration of the second doses began on 16 January 2021.
After the completion of the first groups, the next group in Andalusia will be nearly 413,000 people aged 80 years in March. There could be vaccination bottlenecks here, as this unit cannot benefit from AstraZeneca’s vaccine, which has now been approved by the European Medicines Agency. As in Germany, this is not administered to people over 65 due to a lack of control data. The Russian vaccine Sputnik V is also now being discussed in Spain. Any vaccine approved by the European Medicines Agency (EMA) will be “received with open arms and with enthusiasm”, said the new health minister Carolina Darias in the Spanish parliament yesterday (Wednesday).
Currently, just under 90,000 Andalusians have received both doses. The vaccines are being administered in 37 hospitals in the autonomous region. Seventy-three mobile units are also in operation to administer the doses in senior residences.
How quickly things move forward now depends on the amount of vaccine doses that are actually passed on from the central government to the individual autonomous regions. David Moreno, director of the Vaccination Strategy Centre in Andalusia, says: “At the current pace, we will reach 70 percent of vaccinated people – the so-called herd immunity – only in 2022 and not in the summer of 2021, as the central government continues to claim. More vaccine doses need to be made available urgently.”